BlackRock’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $460M | Buy |
26,562,093
+2,042,901
| +8% | +$28M | 0.01% | 1280 |
|
|
2026
Q1 | $305M | Buy |
24,519,192
+10,220,672
| +71% | +$137M | 0.01% | 1429 |
|
|
2025
Q4 | $180M | Buy |
14,298,520
+224,867
| +2% | +$2.57M | ﹤0.01% | 1751 |
|
|
2025
Q3 | $141M | Buy |
14,073,653
+1,942,294
| +16% | +$17.4M | ﹤0.01% | 1885 |
|
|
2025
Q2 | $98.1M | Sell |
12,131,359
-456,419
| -4% | -$3.44M | ﹤0.01% | 2059 |
|
|
2025
Q1 | $105M | Sell |
12,587,778
-232
| -0% | -$1.94K | ﹤0.01% | 1956 |
|
|
2024
Q4 | $99.7M | Buy |
12,588,010
+177,458
| +1% | +$1.49M | ﹤0.01% | 2090 |
|
|
2024
Q3 | $103M | Buy |
12,410,552
+1,128,122
| +10% | +$8.82M | ﹤0.01% | 2065 |
|
|
2024
Q2 | $71.6M | Buy |
11,282,430
+2,118,258
| +23% | +$13.4M | ﹤0.01% | 2224 |
|
|
2024
Q1 | $55.5M | Buy |
9,164,172
+317,751
| +4% | +$1.79M | ﹤0.01% | 2385 |
|
|
2023
Q4 | $53.7M | Buy |
8,846,421
+813,912
| +10% | +$3.63M | ﹤0.01% | 2432 |
|
|
2023
Q3 | $33.9M | Buy |
8,032,509
+24,513
| +0.3% | +$91.4K | ﹤0.01% | 2631 |
|
|
2023
Q2 | $24.8M | Buy |
8,007,996
+778,523
| +11% | +$1.66M | ﹤0.01% | 2897 |
|
|
2023
Q1 | $10M | Sell |
7,229,473
-67,150
| -0.9% | -$134K | ﹤0.01% | 3321 |
|
|
2022
Q4 | $14.5M | Buy |
7,296,623
+235,217
| +3% | +$527K | ﹤0.01% | 3199 |
|
|
2022
Q3 | $14.3M | Sell |
7,061,406
-393,996
| -5% | -$1.1M | ﹤0.01% | 3227 |
|
|
2022
Q2 | $23.7M | Buy |
7,455,402
+372,700
| +5% | +$1.35M | ﹤0.01% | 2997 |
|
|
2022
Q1 | $29.5M | Buy |
7,082,702
+91,072
| +1% | +$403K | ﹤0.01% | 2923 |
|
|
2021
Q4 | $33.5M | Buy |
6,991,630
+44,741
| +0.6% | +$223K | ﹤0.01% | 2947 |
|
|
2021
Q3 | $37.1M | Sell |
6,946,889
-146,938
| -2% | -$740K | ﹤0.01% | 2859 |
|
|
2021
Q2 | $36.3M | Sell |
7,093,827
-570,965
| -7% | -$3.25M | ﹤0.01% | 2912 |
|
|
2021
Q1 | $51.6M | Buy |
7,664,792
+257,997
| +3% | +$1.43M | ﹤0.01% | 2590 |
|
|
2020
Q4 | $33.8M | Sell |
7,406,795
-918,690
| -11% | -$4.07M | ﹤0.01% | 2713 |
|
|
2020
Q3 | $32.3M | Sell |
8,325,485
-361,192
| -4% | -$1.54M | ﹤0.01% | 2558 |
|
|
2020
Q2 | $41.3M | Sell |
8,686,677
-613,296
| -7% | -$2.53M | ﹤0.01% | 2373 |
|
|
2020
Q1 | $32.4M | Sell |
9,299,973
-94,651
| -1% | -$401K | ﹤0.01% | 2332 |
|
|
2019
Q4 | $45.3M | Buy |
9,394,624
+1,866,574
| +25% | +$6.49M | ﹤0.01% | 2426 |
|
|
2019
Q3 | $21.8M | Buy |
7,528,050
+1,133,127
| +18% | +$3.95M | ﹤0.01% | 2762 |
|
|
2019
Q2 | $45.9M | Buy |
6,394,923
+549,217
| +9% | +$5.62M | ﹤0.01% | 2368 |
|
|
2019
Q1 | $82.8M | Sell |
5,845,706
-208,021
| -3% | -$2.75M | ﹤0.01% | 1988 |
|
|
2018
Q4 | $81.9M | Buy |
6,053,727
+121,800
| +2% | +$2.19M | ﹤0.01% | 1949 |
|
|
2018
Q3 | $132M | Buy |
5,931,927
+123,844
| +2% | +$2.61M | 0.01% | 1777 |
|
|
2018
Q2 | $95.3M | Buy |
+5,808,083
| New | +$102M | ﹤0.01% | 1969 |
|
Other funds holding AMRX
TGA
RCMNY
BlackRock's AMRX Position: Q2 2026 in Review
BlackRock increased its Amneal Pharmaceuticals (AMRX) stake by 8.3% in Q2 2026, buying an estimated $28M and bringing the position to 26,562,093 shares worth $460M. The position accounts for 0.01% of the portfolio, ranked #1280.
BlackRock first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- BlackRock held 26,562,093 shares of Amneal Pharmaceuticals worth $460M as of Q2 2026.
- BlackRock bought 2,042,901 Amneal Pharmaceuticals shares in Q2 2026, an estimated $28M.
- Amneal Pharmaceuticals made up 0.01% of BlackRock's portfolio in Q2 2026, its #1280 holding.
- BlackRock first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.